- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.05. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 3 | SEC Filings | ||
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.04. | Protagenic Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:14 an | 2 | Investing.com Deutsch | ||
| 29.04. | Protagenic Therapeutics announces 1-for-14 reverse stock split | 1 | Investing.com | ||
| 29.04. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split | 245 | ACCESS Newswire | Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics"... ► Artikel lesen | |
| 18.04. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Protagenic Therapeutics, Inc.\new - 10-K, Annual Report | 3 | SEC Filings | ||
| 24.02. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 10.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | Protagenic Therapeutics files to sell 5.84M shares | 5 | Seeking Alpha | ||
| 20.12.24 | Protagenic Therapeutics, Inc.\new - S-1, General form for registration of securities | - | SEC Filings | ||
| 03.12.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 22.11.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million | 439 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that... ► Artikel lesen | |
| 29.10.24 | Protagonist Therapeutics: Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million | 376 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it... ► Artikel lesen | |
| 22.05.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychi | 341 | ACCESS Newswire | No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,094 | +0,72 % | EQS-News: CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit... ► Artikel lesen | |
| VALNEVA | 2,810 | +0,43 % | Valneva: Aktie trotzt negativen News | Die Aktie von Valneva kann sich auch zum Wochenstart gut behaupten. Trotz negativer News zum Chikungunya-Impfstoff IXCHIQ ist das Papier im Tagesverlauf auf der Handelsplattform Tradegate ins Plus gedreht.... ► Artikel lesen | |
| BIOFRONTERA | 2,650 | 0,00 % | Biofrontera verlängert Ameluz-Patent für Aknebehandlung bis 2043 | ||
| PALATIN TECHNOLOGIES | 0,100 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | 0,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,750 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| OCUGEN | 0,629 | -0,82 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,396 | -1,83 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,430 | -0,33 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| BIO-GATE | 0,685 | 0,00 % | Bio-Gate startet Produkt-Launch für Tierpflege in den USA | Bio-Gate hat die Präsenz im nordamerikanischen Veterinärmarkt ausgebaut. Gemeinsam mit einem internationalen Anbieter bringt Bio-Gate neue Tierpflegeprodukte zur Haut-, Ohr- und Wundbehandlung in die... ► Artikel lesen | |
| EDITAS MEDICINE | 1,277 | +2,36 % | Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting | Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,574 | -0,69 % | Evotecs KI-Goldgrube, Defence Therapeutics Milliarden-Märkte, Novo Nordisks Diät-Revolution: So verdienen Anleger mit | Die Gesundheitsbranche befindet sich im Umbruch. Algorithmen beschleunigen die Arzneimittelforschung um Jahre, Milliarden fließen in personalisierte Therapien, und Börsen feiern Biotech-Aktien. Doch... ► Artikel lesen | |
| VAXART | 0,369 | -2,54 % | Vaxart, Inc.: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority... ► Artikel lesen |
PROTAGENIC THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,994 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.